High-density lipoproteins: From function to therapy

Journal of the American College of Cardiology

Volumn 60, Issue 23, 2012, Pages 2380-2383

  Zheng, Chunyu ^a   Aikawa, Masanori ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

atherosclerosis; HDL; kidney; macrophage; statin

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHOLIPASE A2; PLACEBO; SERUM AMYLOID A; TORCETRAPIB;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HYPOALPHALIPOPROTEINEMIA; KIDNEY FAILURE; LIPID METABOLISM; MEDICAL RESEARCH; NOTE; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN SECRETION; PROTEIN TARGETING; RISK ASSESSMENT; VASCULITIS;

EID: 84870542019     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.08.999     Document Type: Editorial

References (28)

1. W.E. Boden High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial Am J Cardiol 86 2000 19L 22L
2. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease The Framingham Study Am J Med 62 1977 707 714 (Pubitemid 8110784)
3. D. Duffy, D.J. Rader Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport Circulation 113 2006 1140 1150
4. H.B. Brewer Jr Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease J Clin Endocrinol Metab 96 2011 1246 1257
5. P. Libby, M. Aikawa Stabilization of atherosclerotic plaques: new mechanisms and clinical targets Nat Med 8 2002 1257 1262 (Pubitemid 35373557)
6. B. Mihaylova, J. Emberson, L. Blackwell The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
7. P.J. Barter, M. Caulfield, M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
8. Roche Provides Update on Phase III Study of Dalcetrapib Roche Global Website http://www.roche.com/media/media-releases/med-cor-2012-05-07.htm Accessed September 28, 2012
9. W.E. Boden, J.L. Probstfield, T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
10. B.F. Voight, G.M. Peloso, M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study Lancet 380 2012 572 580
11. A.R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, N. Wang HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab 7 2008 365 375 (Pubitemid 351598023)
12. M. Navab, S.T. Reddy, B.J. Van Lenten, G.M. Anantharamaiah, A.M. Fogelman The role of dysfunctional HDL in atherosclerosis J Lipid Res 50 Suppl 2009 S145 S149
13. M.K. Jensen, E.B. Rimm, J.D. Furtado, F.M. Sacks Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease J Am Heart Assoc 2012 April 24 [Epub ahead of print]
14. C. Zheng, V. Azcutia, E. Aikawa Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion Eur Heart J 2012 Aug 26 [Epub ahead of print]
15. F.M. Sacks, C. Zheng, J.S. Cohn Complexities of plasma apolipoprotein C-III metabolism J Lipid Res 52 2011 1067 1070
16. P.O. Attman, O. Samuelsson, P. Alaupovic Lipoprotein metabolism and renal failure Am J Kidney Dis 21 1993 573 592 (Pubitemid 23178473)
17. C. Baigent, M.J. Landray, C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
18. S. Yamamoto, P.G. Yancey, T.A. Ikizler Dysfunctional high-density lipoprotein in chronic hemodialysis patients J Am Coll Cardiol 60 2012 2372 2379
19. M. Holzer, R. Birner-Gruenberger, T. Stojakovic Uremia alters HDL composition and function J Am Soc Nephrol 22 2011 1631 1641
20. X. Hu, J.D. Dietz, C. Xia Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 2009 2211 2219
21. S.J. Nicholls, H.B. Brewer, J.J. Kastelein Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
22. C.P. Cannon, S. Shah, H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
23. B. Hewing, E.A. Fisher Rationale for cholesteryl ester transfer protein inhibition Curr Opin Lipidol 23 2012 372 376
24. S.E. Nissen, T. Tsunoda, E.M. Tuzcu Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300 (Pubitemid 37430562)
25. P. Dimayuga, J. Zhu, S. Oguchi Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice Biochem Biophys Res Commun 264 1999 465 468 (Pubitemid 29516109)
26. D. Bailey, R. Jahagirdar, A. Gordon RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589
27. A.V. Khera, M. Cuchel, M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
28. W. Jang, J. Shim, D.Y. Lee, P. Dutta, J.R. Kim, K.H. Cho Rapid detection of dysfunctional high-density lipoproteins using isoelectric focusing-based microfluidic device to diagnose senescence-related disease Electrophoresis 32 2011 3415 3423